At a glance
ClinicalIndex Comparison RecordN/ACompleted· 61 enrolled
Drug / intervention
Bradykinin +5 moredrug
Likely dose
Aspirin 81 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Effects of Rapid-Release Aspirin and NHP-544C on Basal and Bradykinin Stimulated Prostacyclin Production
In Brief
A clinical study evaluating Bradykinin, Aspirin 81 mg, and 4 other interventions for Healthy. Completed, enrolled 61 participants across 1 site.
Detailed Summary
The investigators will compare the effects of rapid release aspirin and NHP-544C on the prostacyclin response to intravenous bradykinin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJul 2014
First PostedJul 2014
Primary CompletionJul 2015
TodayJul 2026
First PostedJul 14, 2014
Enrollment StartJul 1, 2014
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 12.0 years ago
Interventions
Bradykinindrug
Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Aspirin 81 mgdrug
Subjects will take Aspirin 81 mg per day for five days.
Aspirin 162 mgdrug
Subjects will take aspirin 162 mg per day for 5 days.
NHP544-C 81 mgdrug
Subjects will take NHP544C 81 mg per day for five days.
NHP544C 162 mgdrug
Subjects will take NHP544C 162 mg once a day for five days.
Placebodrug
Subjects will take matching placebo for five days.